QuantRx Biomedical Corporation (QTXB)
- Previous Close
0.0040 - Open
0.0040 - Bid 0.0600 x 5000
- Ask 0.0950 x 5000
- Day's Range
0.0040 - 0.0040 - 52 Week Range
0.0002 - 0.0100 - Volume
50,000 - Avg. Volume
1,312 - Market Cap (intraday)
314,786 - Beta (5Y Monthly) -2.07
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon.
www.quantrx.com/index.htmRelated News
Performance Overview: QTXB
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QTXB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QTXB
Valuation Measures
Market Cap
314.79k
Enterprise Value
3.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-72.26
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-209.57%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-260.51k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
3.88k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
125.17k
Company Insights: QTXB
QTXB does not have Company Insights